BRAF

Where the papers sit

21 papers from the last 6 months study BRAF directly · updated from PubMed 1 Nov 2026

• Melanoma Treatment Sequencing

  BRAF/MEK inhibition is being integrated with surgery, molecular pathology and biomarker-guided treatment for advanced melanoma. Brain and in-transit metastases remain central clinical settings, with outcomes varying by treatment strategy. pTERT promoter subtypes and circulating thymidine kinase activity may help predict survival and sequence therapy. Pre-operative circulating tumour DNA is moving toward feasibility testing for risk assessment and response monitoring.

  5 papers · 23.8%

• BRAF MAPK Signaling

  BRAF regulation and MAPK signaling are being connected to tumour progression, inhibitor design and treatment toxicity. ZDHHC5-mediated BRAF palmitoylation activates MAPK signaling in cholangiocarcinoma, highlighting post-translational control as a therapeutic target. New pyrimidine and benzofuran compounds seek selective BRAF or dual VEGFR-2/BRAF inhibition with apoptosis induction. Real-world adverse-event analysis and protein-interaction mapping broaden the focus from kinase blockade to safety and network context.

  5 papers · 23.8%

• Targeted Therapy in BRAF-Altered Cancers

  BRAF fusions and acquired BRAF alterations are driving targeted treatment across NSCLC and rare hematologic cancers. In EGFR-mutant NSCLC, adding selumetinib after osimertinib progression seeks to overcome MAPK-mediated resistance. BRAF/MEK inhibition produces responses in histiocytic sarcoma, while vemurafenib plus rituximab is being used in hairy cell leukemia. Durable benefit remains dependent on the alteration, disease context and treatment sequence.

  4 papers · 19%

• Others — Molecular Cancer Research

  Biomarker-guided treatment, molecular diagnostics and drug discovery appear across colorectal, urothelial, thyroid and glioma research. Anti-EGFR outcomes in colorectal cancer are being linked to systemic inflammation and AREG or EREG biology, while biomarker-defined benefit is explored in urothelial cancer. Other work develops mutant BRAF molecular glues, spatial pathology tools and disease-specific treatment guidance. The group has no single clinical direction beyond expanding molecular stratification.

  7 papers · 33.3%